{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:02:01Z","timestamp":1790895721329,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ygyno.2020.07.026","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:21:02Z","timestamp":1596500462000},"page":"142-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer"],"prefix":"10.1016","volume":"159","author":[{"given":"Andres","family":"Redondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Dreosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Nogueira-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Estevez-Diz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Irahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Donica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2020.07.026_bb0005","doi-asserted-by":"crossref","first-page":"744","DOI":"10.5306\/wjco.v5.i4.744","article-title":"Update on prevention and screening of cervical cancer","volume":"5","author":"McGraw","year":"2014","journal-title":"World J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.07.026_bb0010","first-page":"319","article-title":"Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review","volume":"19","author":"Shrestha","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"10167","key":"10.1016\/j.ygyno.2020.07.026_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ygyno.2020.07.026_bb0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.07.026_bb0025","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2147\/OTT.S68286","article-title":"Angiogenesis and antiangiogenic agents in cervical cancer","volume":"7","author":"Tomao","year":"2014","journal-title":"Onco Targets Ther."},{"issue":"7","key":"10.1016\/j.ygyno.2020.07.026_bb0030","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.07.026_bb0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2013.10.022","article-title":"RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma","volume":"88","author":"Schefter","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.ygyno.2020.07.026_bb0040","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.07.026_bb0045","author":"Avastin Summary of Product Characteristics"},{"key":"10.1016\/j.ygyno.2020.07.026_bb0050","author":"Avastin Prescribing Information"},{"issue":"suppl_4","key":"10.1016\/j.ygyno.2020.07.026_bb0055","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.026_bb0060","author":"NCCN Clinical Practice Guidelines in Oncology"},{"issue":"12","key":"10.1016\/j.ygyno.2020.07.026_bb0065","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s12094-015-1452-2","article-title":"SEOM guidelines for cervical cancer","volume":"17","author":"Oaknin","year":"2015","journal-title":"Clin. Transl. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.07.026_bb0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12094-019-02271-z","article-title":"SEOM clinical guidelines for cervical cancer (2019)","volume":"22","author":"de Juan","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.026_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100557","article-title":"Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer","author":"Choi","year":"2020","journal-title":"Curr. Probl. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2020.07.026_bb0080","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s12094-017-1808-x","article-title":"Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in \u201creal world\u201d patients","volume":"20","author":"Godoy-Ortiz","year":"2018","journal-title":"Clin. Transl. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2020.07.026_bb0085","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/COC.0000000000000403","article-title":"Hypoalbuminemia is a predictive factor for fistula formation in recurrent cervical cancer","volume":"41","author":"Palavalli Parsons","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2020.07.026_bb0090","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2020.07.026_bb0095","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2020.07.026_bb0100","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2020.07.026_bb0105","first-page":"40","article-title":"Recurrent cervical cancer with intestinal perforation that was related to bevacizumab after long-term NSAIDs administration and was treated with laparoscopy-assisted anastomosis","volume":"44","author":"Iida","year":"2019","journal-title":"Tokai J. Exp. Clin. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2020.07.026_bb0110","doi-asserted-by":"crossref","first-page":"863","DOI":"10.21873\/invivo.11551","article-title":"Bevacizumab efficacy and recurrence pattern of persistent and metastatic cervical cancer","volume":"33","author":"Lee","year":"2019","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.ygyno.2020.07.026_bb0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00261-012-9913-3","article-title":"Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients","volume":"38","author":"Borofsky","year":"2013","journal-title":"Abdom. Imaging"},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2020.07.026_bb0120","article-title":"Fistulae in women treated with chemotherapy with and without bevacizumab for persistent, recurrent or metastatic cervical cancer in GOG-240","volume":"24","author":"Willmott","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2020.07.026_bb0125","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group Study","volume":"32","author":"Burger","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.026_bb0130","author":"Roche","year":"2014"},{"issue":"6","key":"10.1016\/j.ygyno.2020.07.026_bb0135","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/IGC.0000000000001000","article-title":"Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer","volume":"27","author":"Rosen","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2020.07.026_bb0140","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ejca.2012.02.052","article-title":"Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study","volume":"48","author":"Kabbinavar","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"10103","key":"10.1016\/j.ygyno.2020.07.026_bb0145","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2020.07.026_bb0150","first-page":"6","article-title":"Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group","volume":"3","author":"Friedlander","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.07.026_bb0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ijgc-2019-000880","volume":"30","author":"Grau","year":"2020","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820336611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820336611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:50:42Z","timestamp":1758772242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820336611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0090825820336611"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.026","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}